InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,221.42
(
-0.02%
)
US TECH 100
17,710.40
(
0.16%
)
Dow Jones
39,431.51
(
-0.21%
)
Brent Oil
83.21
(
1.00%
)
Bitcoin
62,758.59
(
2.13%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 217

Sunday, 06/24/2018 7:17:02 PM

Sunday, June 24, 2018 7:17:02 PM

Post# of 438
INFI recently showed progress by presenting encouraging data at ASCO 2018

The bull case for INFI revolves around the possiblity of an effective combo therapy with Opdivo (nisolumab)

The ASCO data showed that IPI-549 in combination with Opdivo showed 40% durable disease control in Adrenocortical Cancer

In addition, VSTM will owe INFI a $22mn payment if duvelismib gains PDUFA approval in 10/18.

With this payment, INFI would have a cash runway into Q4/19. Without it, they will only make it thru Q1/19.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up